BiondVax Pharmaceuticals Ltd (BVXV)

[midastouch017]

BiondVax gains on collaboration to develop nanosized COVID-19 antibody therapy

Dec. 22, 2021 9:06 AM ETBiondVax Pharmaceuticals Ltd. (BVXV)

By: Dulan Lokuwithana, SA News Editor


Nano-cap stock, BiondVax Pharmaceuticals (NASDAQ:BVXV) has more than doubled in the pre-market on above-average volume after announcing the signing of definitive agreements with two German institutes for the development and commercialization of COVID-19 nanosized antibodies.

The agreements with Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) are part of a broader partnership expected to be signed in Jan. 2022, the company announced.

The lead NanoAb COVID-19 candidates in the program have a robust competitive advantage over the current treatments for the disease, BiondVax (BVXV) argues. The company cites their ability to bind the target at concentrations 100-times lower than those required by commercially available monoclonal antibody treatments for COVID-19.
In addition, their smaller size and hyper-thermostability should enable an inhalational mode of administration with longer shelf life and avoid the need for enhanced cold chain storage, according to BiondVax (BVXV).

The company expects to advance preclinical studies for COVID-19 NanoAb in 2022, with data from early human clinical trials anticipated in 2023.

Israel-based BiondVax (BVXV) announced a 5-year strategic research collaboration with the two German institutes in October. The deal was subject to the execution of definitive agreements, the company said at the time.